Energy metabolism, leptin, and biochemical parameters are altered in rats subjected to the chronic administration of olanzapine;Metabolismo calórico, leptina e parâmetros bioquímicos se alteram em ratos submetidos à administração crônica de olanzapina

Revista Brasileira de Psiquiatria

Volumn 34, Issue 2, 2012, Pages 168-175

  Zugno, Alexandra I ^a   Barcelos, Mariely ^a   de Oliveira, Larissa ^a   Canever, Leila ^a   de Luca, Renata D ^a   Fraga, Daiane B ^a   Matos, Maria Paula ^a   Rezin, Gislaine T ^a   Scaini, Giselli ^a   Búrigo, Márcio ^a   Streck, Emilio L ^a   Quevedo, João ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Cafeteria diet; Energy metabolism; Leptin; Olanzapine; Schizophrenia

Indexed keywords

CHOLESTEROL; CYTOCHROME C OXIDASE; GLUCOSE; LEPTIN; OLANZAPINE; SUCCINATE DEHYDROGENASE (UBIQUINONE); TRIACYLGLYCEROL; WATER;

ANIMAL EXPERIMENT; ARTICLE; BIOCHEMISTRY; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME ACTIVITY; FEEDING; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; LIVER; MALE; METABOLIC DISORDER; MUSCLE; NONHUMAN; OBESITY; RAT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 84863736497     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-44462012000200009     Document Type: Article

References (40)

1. Sa Junior AR, Souza MC. Avaliação do comprometimento funcional na esquizofrenia. Rev Psiq Clín. 2007;34:164-8.
2. Harrison PJ. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain. 1999;122(4):593-624.
3. Elkis H, Gama C, Suplicy H, Tambascia M, Bressan R, Lyra R, Cavalcante S, Minicucci W. Consenso brasileiro sobre antipsicóticos de segunda geração e distúrbios metabólicos. Rev Bras Psiquitr. 2008;30(1):77-85.
4. Medeiros FL, Andrade AG, Hiroce VY, Alves TCTF. Síndrome neuroléptica maligna de paciente em uso de olanzapina. J Bras Psiq. 2008;57(2):20-7.
5. Reinke A, Martins MR, Lima MS, Moreira JC, Dal-Pizzol F, Quevedo J. Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosc Lett. 2004;372(1-2):157-60.
6. Azevedo CLL, Guimarães LR, Lobato MI, Abreu PB. Ganho de peso e alterações metabólicas em esquizofrenia. Rev Psiq Clín. 2007;34(2):36-8.
7. Jacob R, Chowdhury AN. Metabolic comorbidity in schizophrenia. Indian J Med Sci. 2008;62(1):23-31.
8. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia. Int J Obesit Relat Metab Disord. 2002;26(1):137-41.
9. Oliveira IR. Antipsicóticos atípicos: farmacologia e uso clínico. Rev Bras Psiquiatr. 2000;22(1):19-25.
10. Nasrallah HA, Newcomer JW. Atypical antipsychotic and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004;24(1):7-14.
11. Bear MF, Connors BW, Paradiso MA. Neurociências: desvendando o sistema nervoso. In: A Regulação em Longo Prazo do Comportamento Alimentar. Artmed Editora, Porto Alegre, 2002; pp. 524-41.
12. Zhang F, Chen J. Leptin protects hippocampal CA1 neurons against ischemic injury. J Neurochem. 2008;107(2):578.
13. Carvalheira JB, Siloto RM, Ignacchitti I, Brenelli SL, Carvalho CR, Leite A, Velloso LA, Gontijo JA, Saad MJ. Insulin modulates leptin-induced STAT3 activation in rat hypothalamus. FEBS Lett. 2001;500(3):119-24.
14. Zhang XY, Tan YL, Zhou DF, Haile CN, Cao LY, Xu Q, Shen Y, Kosten TA, Kosten TR. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol. 2007;27(3):246-51.
15. Wang HC, Chen PS, Lee IH, Yang YK, Yeh TL, Lu RB. Rapid leptin elevation after initiation of olanzapine? Neuropsychobiol. 2007;54(3):182-5.
16. Dallaporta M, Pecchi E, Pio J, Jean A, Horner KC, Troadec JD. Expression of leptin receptor by glial cells of the nucleus tractus solitaries: possible involvement in energy homeostasis. J Neuroendocrinol. 2009;21(1):57-67.
17. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care. 2003;26(5):1589-96.
18. Albaugh VL, Vary TC, Ilkayeva O, Wenner BR, Maresca KP, Joyal JL, Breazeale S, Elich TD, Lang CH, Lynch CJ. Atypical Antipsychotics Rapidly and Inappropriately Switch Peripheral Fuel Utilization to Lipids, Impairing Metabolic Flexibility in Rodents. Schizop Bull. 2010: in press.
19. Deveaud C, Beauvoit B, Salin B, Schaeffer J, Rigoulet M. Regional differences in oxidative capacity of rat white adipose tissue are linked to the mitochondrial content of mature adipocytes. Mol Cell Biochem. 2004;267(1-2):157-66.
20. Balijepalli S, Boyd MR, Ravindranath V. Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation. Neuropharmacol. 1999;38(4):567-77.
21. Balijepalli S, Kenchappa RS, Boyd MR, Ravindranath V. Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics. Neurochem Int. 2001;38:425-35.
22. Ji B, La Y, Gao L, Zhu H, Tian N, Zhang M, Yang Y, Zhao X, Tang R, Ma G, Zhou J, Meng J, Ma J, Zhang Z, Li H, Feng G, Wang Y, He L, Wan C. A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. J Proteome Res. 2009;8(7):3633-41.
23. Ben-Shachar D. Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J Neurochem. 2002;83(6):1241-51.
24. Ben-Shachar D, Zuk R, Gazawi H, Ljubuncic P. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders. Biochem Pharmacol. 2004;67(10):1965-74.
25. Rustin P, Chretien D, Bourgeron T, Gérard B, Rotig A, Saudubray JM, Munnich A.. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta. 1994;228(1):35-51.
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265-75.
27. Teixeira PJR, Rocha FL. Efeitos adversos metabólicos de antipsicóticos e estabilizadores de humor. Rev Psiq RG. 2006;28(2):186-96.
28. Koro C, Fedder D, Gilbert J, Weiss S, Magder L, Revichi D, Buchanan RW.. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipemia in schizophrenia patients. Arch Gen Psychiat. 2002;59(11):1021-6.
29. Sheitman B, Bird P, Binz W, Akinli L, Sanchez C. Olanzapineinduced elevation of plasma triglyceride levels. Am J Psychiat. 1999;156(9):1471-2.
30. Sena EP, Sampaio AS, Quarantini LC, Oliveira IR. Diabetes mellitus e antipsicóticos atípicos. Rev Bras Psiquiat. 2003;25(4):253-7.
31. Gorobets LN. Contribution of leptin to the formation of neuroleptic obesity in patients with schizophrenia during antipsychotic therapy. Bull Exp Biol Med. 2008;146(3)348-50.
32. Coccurello R, Caprioli A, Ghirardi O, Conti R, Ciani B, Daniele S, Bartolomucci A, Moles A. Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacol. 2006;186(4):561-71.
33. Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapineinduced glucose dysregulation. Ann Pharmacother. 2000;34(7-8):865-7.
34. Ebenbichler C, Laimer M, Kranebitter M, Lechleitner M, Patsch JR, Baumgartner S, Edlinger M, Hofer A, Hummer M, Rettenbacher MA, Fleischhacker WW. The soluble leptin receptor in olanzapineinduced weight gain: results from a prospective study. Schizop Res. 2005;75(1):143-6.
35. Wang HC, Chen PS, Lee IH, Yang YK, Yeh TL, Lu RB. Rapid leptin elevation after initiation of olanzapine? Neuropsychobiol. 2006;54(3):182-5.
36. Donna A, Wirshing MD, Joseph M, Pierre MD, Stephen M, Erhart MD, Jennifer A. Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiat Clin North Am. 2003;26(1):165-90.
37. Danaci AE, Sarandol A, Taneli F, Yurtsever F, Ozlen N. Effects of second generation antipsychotics on leptin and ghrelin. Neuro-Psychopharmacol & Biol Psychiat. 2008;32(6):1434-8.
38. Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL. Mitchondrial dysfunction and psychiatric disorders. Neurochem Res. 2009;34(6):L1021-9.
39. Porter R, Brand M. Body mass dependence of H+ leak in mitochondria and its relevance to metabolic rate. Nat. 1993;362(6421):628-30.
40. Streck EL, Rezin GT, Barbosa LM, Assis LC, Grandi E, Quevedo J.. Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain. Naunyn-Schmiedeberg's Arch Pharmacol. 2007;376(1-2):127-33.